Literature DB >> 29016510

Comparative Effectiveness of Uterine Leiomyoma Procedures Using a Large Insurance Claims Database.

Bijan J Borah1, Xiaoxi Yao, Shannon K Laughlin-Tommaso, Herbert C Heien, Elizabeth A Stewart.   

Abstract

OBJECTIVE: To compare risk of reintervention, long-term clinical outcomes, and health care utilization among women who have bulk symptoms from leiomyoma and who underwent the following procedures: hysterectomy, myomectomy, uterine artery embolization, and magnetic resonance-guided, focused ultrasound surgery.
METHODS: This was a retrospective analysis of administrative claims from a large U.S. commercial insurance database. Women aged 18-54 years undergoing any of the previously mentioned leiomyoma procedures between 2000 and 2013 were included. We assessed the following outcome measures: risk of reintervention between uterine-sparing procedures, risk of other surgical procedures or complications of the index procedure, 5-year health care utilization, pregnancy rates, and reproductive outcomes. Propensity score matching along with Cox proportional hazard models were used to adjust for differences in baseline characteristics between study cohorts.
RESULTS: Among the 135,522 study-eligible women with mean follow-up of 3.4 years, hysterectomy was the most common first-line procedural therapy (111,324 [82.2%]) followed by myomectomy (19,965 [14.7%]), uterine artery embolization (4,186 [3.1%]) and magnetic resonance-guided focused ultrasound surgery (47 [0.0003%]). Small but statistically significant differences were noted for uterine artery embolization and myomectomy in reintervention rate (17.1% compared with 15.0%, P=.02), subsequent hysterectomy rates (13.2% compared with 11.1%, P<.01) and subsequent complications from index procedures (18.1% compared with 24.6%, P<.001). During follow-up, women undergoing myomectomy had lower leiomyoma-related health care utilization, but had higher all-cause outpatient services. Pregnancy rates were 7.5% and 2.2% among myomectomy and uterine artery embolization cohorts, respectively (P<.001) with both cohorts having similar rates of adverse reproductive outcome (69.4%).
CONCLUSIONS: Although the overwhelming majority of women having leiomyoma with bulk symptoms underwent hysterectomy as their first treatment procedure, among those undergoing uterine-sparing index procedures, approximately one seventh had a reintervention, and one tenth ended up undergoing hysterectomy during follow-up. Compared with women undergoing myomectomy, women undergoing uterine artery embolization had a higher risk of reintervention, lower risk of subsequent complications, but similar rate of adverse reproductive outcomes.

Entities:  

Mesh:

Year:  2017        PMID: 29016510      PMCID: PMC5683097          DOI: 10.1097/AOG.0000000000002331

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  29 in total

1.  Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study.

Authors:  Thien Kieu Thi Phung; Berit Lindum Waltoft; Thomas Munk Laursen; Annette Settnes; Lars Vedel Kessing; Preben Bo Mortensen; Gunhild Waldemar
Journal:  Dement Geriatr Cogn Disord       Date:  2010-07-30       Impact factor: 2.959

Review 2.  Pregnancy outcomes following treatment for fibroids: uterine fibroid embolization versus laparoscopic myomectomy.

Authors:  Jay Goldberg; Leonardo Pereira
Journal:  Curr Opin Obstet Gynecol       Date:  2006-08       Impact factor: 1.927

3.  Health care resource use for uterine fibroid tumors in the United States.

Authors:  Michael Flynn; Margaret Jamison; Santanu Datta; Evan Myers
Journal:  Am J Obstet Gynecol       Date:  2006-05-24       Impact factor: 8.661

4.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

5.  Uterine fibroid embolization versus myomectomy in women wishing to preserve fertility: preliminary results of a randomized controlled trial.

Authors:  Michal Mara; Zuzana Fucikova; Jana Maskova; David Kuzel; Lucia Haakova
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2005-11-15       Impact factor: 2.435

6.  Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study.

Authors:  Barbara V Howard; Lewis Kuller; Robert Langer; JoAnn E Manson; Catherine Allen; Annlouise Assaf; Barbara B Cochrane; Joseph C Larson; Norman Lasser; Monique Rainford; Linda Van Horn; Marcia L Stefanick; Maurizio Trevisan
Journal:  Circulation       Date:  2005-03-21       Impact factor: 29.690

7.  Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial.

Authors:  Gaylene Pron; Eva Mocarski; John Bennett; George Vilos; Andrew Common; Leslie Vanderburgh
Journal:  Obstet Gynecol       Date:  2005-01       Impact factor: 7.661

8.  Inpatient hysterectomy surveillance in the United States, 2000-2004.

Authors:  Maura K Whiteman; Susan D Hillis; Denise J Jamieson; Brian Morrow; Michelle N Podgornik; Kate M Brett; Polly A Marchbanks
Journal:  Am J Obstet Gynecol       Date:  2007-11-05       Impact factor: 8.661

9.  Nationwide trends in the performance of inpatient hysterectomy in the United States.

Authors:  Jason D Wright; Thomas J Herzog; Jennifer Tsui; Cande V Ananth; Sharyn N Lewin; Yu-Shiang Lu; Alfred I Neugut; Dawn L Hershman
Journal:  Obstet Gynecol       Date:  2013-08       Impact factor: 7.661

10.  Optum Labs: building a novel node in the learning health care system.

Authors:  Paul J Wallace; Nilay D Shah; Taylor Dennen; Paul A Bleicher; Paul D Bleicher; William H Crown
Journal:  Health Aff (Millwood)       Date:  2014-07       Impact factor: 6.301

View more
  5 in total

1.  Multiparametric MR evaluation of uterine leiomyosarcoma and STUMP versus leiomyoma in symptomatic women planned for high frequency focussed ultrasound: accuracy of imaging parameters and interobserver agreement for identification of malignancy.

Authors:  Parisa Aminzadeh; Ekaterina Alibrahim; Andrew Dobrotwir; Eldho Paul; Stacy Goergen
Journal:  Br J Radiol       Date:  2021-01-28       Impact factor: 3.039

2.  Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.

Authors:  James A Simon; Ayman Al-Hendy; David F Archer; Kurt T Barnhart; Linda D Bradley; Bruce R Carr; Thomas Dayspring; Eve C Feinberg; Veronica Gillispie; Sandra Hurtado; JinHee Kim; Ran Liu; Charlotte D Owens; Ozgul Muneyyirci-Delale; Alice Wang; Nelson B Watts; William D Schlaff
Journal:  Obstet Gynecol       Date:  2020-06       Impact factor: 7.623

Review 3.  Vitamin D and Uterine Fibroids-Review of the Literature and Novel Concepts.

Authors:  Michał Ciebiera; Marta Włodarczyk; Magdalena Ciebiera; Kornelia Zaręba; Krzysztof Łukaszuk; Grzegorz Jakiel
Journal:  Int J Mol Sci       Date:  2018-07-14       Impact factor: 5.923

4.  Alpha-Tocopherol Serum Levels Are Increased in Caucasian Women with Uterine Fibroids: A Pilot Study.

Authors:  Michał Ciebiera; Jolanta Szymańska-Majchrzak; Aleksandra Sentkowska; Krzysztof Kilian; Zbigniew Rogulski; Grażyna Nowicka; Grzegorz Jakiel; Piotr Tomaszewski; Marta Włodarczyk
Journal:  Biomed Res Int       Date:  2018-07-24       Impact factor: 3.411

5.  Reintervention Rates After Myomectomy, Endometrial Ablation, and Uterine Artery Embolization for Patients with Uterine Fibroids.

Authors:  Matthew R Davis; Ahmed M Soliman; Jane Castelli-Haley; Michael C Snabes; Eric S Surrey
Journal:  J Womens Health (Larchmt)       Date:  2018-08-07       Impact factor: 2.681

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.